Now Trending: Insurers Dropping Weight Loss Drug Coverage, FDA Approves Novel Parkinson’s Drug
Drug Topics
AUGUST 10, 2024
Check out this recap of articles published on our sister sites during the past week.
Sat.Aug 10, 2024
247 
Finerenone Significantly Reduces Cardiovascular Death, Heart Failure in the FINEARTS-HF Trial
Pharmacy Times
AUGUST 10, 2024
Non-steroidal mineralocorticoid receptor antagonist, finerenone, demonstrated improved efficacy compared with existing steroidal treatment for patients.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Small Doses: August 5 to August 9
Drug Topics
AUGUST 10, 2024
Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.
FDA Grants Rare Pediatric Disease Designation to SAT-3247 to Treat Duchenne Muscular Dystrophy
Pharmacy Times
AUGUST 10, 2024
The commencement of the phase 1 clinical trial of SAT-3247 is expected in Q3 of 2024.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Opinion: First Opinion readers respond to essays on right to try lies, pharma execs, and more
STAT
AUGUST 10, 2024
First Opinion is STAT’s platform for interesting, illuminating, and maybe even provocative articles about the life sciences writ large, written by biotech insiders, health care workers, researchers, and others. To encourage robust, good-faith discussion about issues raised in First Opinion essays, STAT publishes selected Letters to the Editor received in response to them.
Comparing Viral Vectors for Gene Therapy Delivery
BioPharm
AUGUST 10, 2024
AAV and lentivirus both have pros and cons in their use for specific gene therapy applications.
The Potential for CAR-Ts in Large Patient Populations
BioPharm
AUGUST 10, 2024
The biopharma industry is seeking ways to apply cell and gene therapies to mass patient populations.
Let's personalize your content